. 2018 Dec;11(3):200–208. doi: 10.2174/1874471011666180502104524

Table 1.

Overview of clinical experience with ²²⁵Ac- and ²¹³Bi-labeled compounds.

Cancer type	Radioconjugate	Patients	References
Leukemia	^²¹³Bi-HuM195mAb	49	[38,39]
-	^²²⁵Ac-HuM195mAb	36	[40]
Lymphoma	^²¹³Bi-anti-CD20-mAb	12	[41]
Melanoma	^²¹³Bi-9.2.27mAb	54	[42-44]
Bladder Cancer	^²¹³Bi-anti-EGFR-mAb	12	[32,45]
Glioma	^²¹³Bi-Substance P	68	[46-48]
-	^²²⁵Ac-Substance P	19	[48]
Neuroendocrine tumors	^²¹³Bi-DOTATOC	25	[4]
-	^²²⁵Ac-DOTATOC	39	[49]
Prostate cancer	^²²⁵Ac-PSMA-617	190	[5,50,51]